Life sciences firm Revvity reported Q2 sales of $691.69m, exceeding estimates, and raised FY24 earnings guidance.
Life sciences firm Revvity (NYSE: RVTY) reported Q2 sales of $691.69m, up from the consensus estimate of $690.36m, and Q2 adjusted EPS of $1.22, beating the consensus of $1.12. Revvity raised its FY24 earnings guidance to $4.70-$4.80, and its revenue guidance to $2.77-$2.79bn. The company's Life Sciences revenue was $314m, down 7%, while Diagnostics sales increased 1% YoY to $378m.
July 29, 2024
7 Articles